Several domestic and global brokerage firms have recently initiated coverage on a number of select stocks, expressing positive sentiments towards their future performance. These stocks include SIS, Global Health (Medanta), Rainbow Children’s Medicare (RCML), Aditya Birla Capital (AB Capital), Concord Biotech, IRCON International, Kirloskar Pneumatic, Kajaria Ceramics, Hindware Home Innovation (HHIL), and Senco Gold.
The majority of these stocks have received ‘buy’ ratings from analysts, with upside potential ranging from 22% to 95%. Let’s take a closer look at why these analysts are optimistic about these stocks.
Keynote Capitals has given SIS a ‘buy’ rating with a target price of Rs 837, expecting a 95% upside. The company, formerly known as Security and Intelligence Services (India), has shown steady revenue growth and an expanding customer base. Keynote Capital believes that SIS’s leadership position and areas of strength make it well-positioned to benefit from industry growth over the next three years.
Ambit Capital has initiated coverage on Kirloskar Pneumatic with a ‘buy’ rating and a target price of Rs 912, projecting a 46% upside. The company is expected to benefit from the increasing demand for refrigeration and gas compressors/packages, especially with the growing CNG infrastructure. Ambit highlights Kirloskar Pneumatic’s cost leadership and product additions as catalysts for future growth.
Bonanza Portfolio has recommended a ‘buy’ for Kajaria Ceramics with a target price of Rs 1,803, indicating a potential upside of 36%. The company’s focus on premium tile launches and expanding distribution channels has helped it gain market share and improve pricing power. Bonanza expects Kajaria Ceramics to continue its growth trajectory through CAPEX plans, expansion into non-core businesses, and increasing export opportunities.
Antique Stock Broking has given a ‘buy’ rating to Concord Biotech with a target price of Rs 1,340, expecting a 29% upside. The company, which manufactures APIs via fermentation route, possesses a strong portfolio of products in the immunosuppressant and anti-infective segments. Antique Stock Broking believes Concord Biotech’s robust revenue growth and backward integration strategy will contribute to its future success.
Monarch Networth Capital has initiated coverage on Rainbow Children’s Medicare with a ‘buy’ rating and a target price of Rs 1,296, projecting a 25% upside. As a leader in paediatrics, obstetrics, and gynaecology services, Rainbow Children’s Medicare has witnessed significant growth since its establishment in 1999. The company’s comprehensive healthcare services and strong infrastructure make it a promising investment opportunity.
Jefferies has recommended a ‘buy’ for Aditya Birla Capital with a target price of Rs 215, indicating a potential upside of 22%. The firm believes that AB Capital, with its wider network and higher cross-sells, is well-positioned to double profits in the next three years. Jefferies also expects the company to benefit from opportunities in MSME lending and lower ticket loans.
Antique Stock Broking has given IRCON International a ‘buy’ rating with a target price of Rs 176, projecting a 25% upside. The company, engaged in railway EPC works, has a strong presence in various segments of infrastructure. Antique Stock Broking highlights IRCON International’s asset-light business model and high RoE as key factors for future success.
Overall, analysts are optimistic about the future prospects of these select stocks, supported by factors such as revenue growth, market share expansion, cost leadership, and strong infrastructure. Investors may consider these stocks for their potential upside in the coming years.
– Keynote Capitals Report on SIS
– Ambit Capital Report on Kirloskar Pneumatic
– Bonanza Portfolio Report on Kajaria Ceramics
– Antique Stock Broking Report on Concord Biotech
– Monarch Networth Capital Report on Rainbow Children’s Medicare
– Jefferies Report on Aditya Birla Capital
– Antique Stock Broking Report on IRCON International